Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

NeoGenomics to buy Genoptix

NeoGenomics, Inc., a provider of cancer-focused genetic testing services, has entered into a definitive agreement to acquire Genoptix, Inc. for $125 million in cash and 1 million shares of NeoGenomics common stock., PE Hub reported. Genoptix is a clinical oncology laboratory, specializing in hematology and solid tumor testing and is backed by Ampersand Capital Partners and 1315 Capital. William Blair and Company advised Genoptix on the transaction.


Mergers and Acquisitions,M&A,M&A deals